BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2534278)

  • 1. Protective effects of a combination thromboxane synthesis inhibitor-receptor antagonist, R-68070, during murine traumatic shock.
    Aoki N; Johnson G; Siegfried MR; Lefer AM
    Eicosanoids; 1989; 2(3):169-74. PubMed ID: 2534278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effect of a thromboxane synthetase inhibitor in traumatic shock.
    Hock CE; Lefer AM
    Circ Shock; 1984; 14(3):159-68. PubMed ID: 6542462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial actions of BN 50739, a new PAF receptor antagonist, in murine traumatic shock.
    Karasawa A; Rochester JA; Lefer AM
    Methods Find Exp Clin Pharmacol; 1990 May; 12(4):231-7. PubMed ID: 2165204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of a new LTD4 antagonist (LY-171883) in traumatic shock.
    Hock CE; Lefer AM
    Circ Shock; 1985; 17(4):263-72. PubMed ID: 3841503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shock.
    Bitterman H; Smith BA; Lefer AM
    Arzneimittelforschung; 1988 Oct; 38(10):1389-93. PubMed ID: 3196378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of two leukotriene antagonists in rat traumatic shock.
    Levitt MA; Lefer AM
    Methods Find Exp Clin Pharmacol; 1987 May; 9(5):269-73. PubMed ID: 3613754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of KW-3635, a novel thromboxane A2 antagonist, in murine traumatic shock.
    Karasawa A; Taylor PA; Lefer AM
    Eur J Pharmacol; 1990 Jun; 182(1):1-8. PubMed ID: 2401310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock.
    Bitterman H; Phillips GR; Dragon G; Lefer AM
    J Pharmacol Exp Ther; 1987 Jul; 242(1):8-14. PubMed ID: 3039116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock.
    Stahl GL; Bitterman H; Lefer AM
    Thromb Res; 1989 Feb; 53(3):327-38. PubMed ID: 2718150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of oligotide, a novel oligodeoxyribonucleotide, in murine traumatic shock.
    Skurk C; Nuss C; Lefer AM
    Shock; 1995 Jan; 3(1):13-20. PubMed ID: 7531603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a combination thromboxane receptor antagonist and lipoxygenase inhibitor in traumatic shock.
    Levitt MA; Stahl G; Lefer AM
    Resuscitation; 1988 Jul; 16(3):211-20. PubMed ID: 2845544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective actions of aprotinin in acute traumatic shock.
    Araki H; Lefer AM
    Arch Int Pharmacodyn Ther; 1979 Oct; 241(2):316-23. PubMed ID: 316692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Vercammen E; Freyne E; Janssen PA
    Prog Clin Biol Res; 1989; 301():567-72. PubMed ID: 2529556
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-shock actions of the pyrimido-pyrimidine derivative, RA-642.
    Hock CE; Lefer DJ; Lefer AM
    Methods Find Exp Clin Pharmacol; 1986 May; 8(5):265-9. PubMed ID: 3724301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of the specific thromboxane receptor antagonist (+)-S145Na in splanchnic artery occlusion shock in rats.
    Furlan LE; Johnson G; Siegfried M; Lefer AM
    J Pharmacol Exp Ther; 1990 May; 253(2):525-9. PubMed ID: 2140129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of adenosine, an adenosine-A1 antagonist, and their combination in splanchnic occlusion shock in rats.
    Karasawa A; Rochester JA; Lefer AM
    Circ Shock; 1992 Feb; 36(2):154-61. PubMed ID: 1582007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of thromboxane receptor blockade in splanchnic artery occlusion shock.
    Aoki N; Lefer AM
    Methods Find Exp Clin Pharmacol; 1988 Jul; 10(7):413-8. PubMed ID: 3419244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.